Status and phase
Conditions
Treatments
About
INDICATION:
Patients with chronic hepatitis C, genotype 1 and non-responders to standard treatment for hepatitis C.
OBJECTIVES:
DESIGN OF TEST Pilot Study:
The single arm study will:
Be tracked for 24 weeks after treatment.
Suspended treatment of 12 weeks in patients who have failed a drop of HCV RNA> 2 log.
Patients who have been suspended for any reason, the treatment will be followed during 24 weeks, to assess safety parameters.
SUBJECT NUMBER: 10
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Patients with any of the following will not be selected for treatment:
Primary purpose
Allocation
Interventional model
Masking
10 participants in 1 patient group
Loading...
Central trial contact
Manuel Romero-Gomez, M.D.Ph.D
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal